Abstract

Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.
Original languageEnglish
Title of host publicationAdvances in Treatment of Hepatitis C and B
PublisherInTech
ISBN (Electronic)978-953-51-2994-3
ISBN (Print)978-953-51-2993-6
DOIs
Publication statusPublished - Mar 8 2017

Fingerprint

Virus Internalization
Hepacivirus
Antiviral Agents
Satellite Viruses
End Stage Liver Disease
Virus Diseases
Hepatitis C
Blood Transfusion
Vaccines
Monoclonal Antibodies
Safety
Costs and Cost Analysis
Pharmaceutical Preparations
Population
Therapeutics

Keywords

  • hepatitis C virus
  • viral entry
  • antivirals
  • entry inhibitors
  • monoclonal antibodies
  • small molecules
  • therapeutic plasma products

Cite this

Burnouf, T. P. R., Liu, C. H., & Lin, L-T. (2017). Strategies to Preclude Hepatitis C Virus Entry. In Advances in Treatment of Hepatitis C and B InTech. https://doi.org/10.5772/65470

Strategies to Preclude Hepatitis C Virus Entry. / Burnouf, Thierry Pierre Robert; Liu, Ching Hsuan; Lin, Liang-Tzung.

Advances in Treatment of Hepatitis C and B. InTech, 2017.

Research output: Chapter in Book/Report/Conference proceedingChapter

Burnouf, TPR, Liu, CH & Lin, L-T 2017, Strategies to Preclude Hepatitis C Virus Entry. in Advances in Treatment of Hepatitis C and B. InTech. https://doi.org/10.5772/65470
Burnouf TPR, Liu CH, Lin L-T. Strategies to Preclude Hepatitis C Virus Entry. In Advances in Treatment of Hepatitis C and B. InTech. 2017 https://doi.org/10.5772/65470
Burnouf, Thierry Pierre Robert ; Liu, Ching Hsuan ; Lin, Liang-Tzung. / Strategies to Preclude Hepatitis C Virus Entry. Advances in Treatment of Hepatitis C and B. InTech, 2017.
@inbook{990ca64c818e476f932c84ff240a4750,
title = "Strategies to Preclude Hepatitis C Virus Entry",
abstract = "Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.",
keywords = "hepatitis C virus, viral entry, antivirals, entry inhibitors, monoclonal antibodies, small molecules, therapeutic plasma products",
author = "Burnouf, {Thierry Pierre Robert} and Liu, {Ching Hsuan} and Liang-Tzung Lin",
year = "2017",
month = "3",
day = "8",
doi = "10.5772/65470",
language = "English",
isbn = "978-953-51-2993-6",
booktitle = "Advances in Treatment of Hepatitis C and B",
publisher = "InTech",
address = "Croatia",

}

TY - CHAP

T1 - Strategies to Preclude Hepatitis C Virus Entry

AU - Burnouf, Thierry Pierre Robert

AU - Liu, Ching Hsuan

AU - Lin, Liang-Tzung

PY - 2017/3/8

Y1 - 2017/3/8

N2 - Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.

AB - Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.

KW - hepatitis C virus

KW - viral entry

KW - antivirals

KW - entry inhibitors

KW - monoclonal antibodies

KW - small molecules

KW - therapeutic plasma products

U2 - 10.5772/65470

DO - 10.5772/65470

M3 - Chapter

SN - 978-953-51-2993-6

BT - Advances in Treatment of Hepatitis C and B

PB - InTech

ER -